Sharps Technology Welcomes Robert Hayes to the Sharps Leadership Team

NEW YORK, NY / ACCESSWIRE / September 21, 2021 / Sharps Technology, an innovative medical device company offering patented, best in class, single use smart safety syringe product line, today announced Robert Hayes will be joining the Sharps leadership team as Chief Executive Officer.

About Robert Hayes
Chief Executive Officer

A person wearing a suit and tieDescription automatically generated with medium confidence

Before being named CEO at Sharps Technology, Robert Hayes most recently spent 11 years at Gerresheimer Pharmaceutical Glass where he led commercial sales through strategic partnerships and programs with top global healthcare companies. Most recently as the Senior Director of Innovation and Product Management, he was responsible for overseeing the development and commercialization of specialized pharmaceutical packaging products. Through this role and his previous position as Global Key Account Manager, he created market leading growth within the packaging industry.

Robert has over 25 years’ experience in the healthcare, medical device, and pharmaceutical manufacturing industry, working for companies such as Baxter Healthcare, Cardinal Healthcare, Covidien/Sherwood Medical producing monoject syringes, Boston Scientific, Hollister, Hill-Rom, Fresenius Medical, and CMO Operations, where he supported top leading pharmaceutical companies such as GSK, Pfizer and Merck.

His time in the industry has included leadership positions for plant operations, quality management, validation and technical services for healthcare and medical device manufacturing. He also has experience in development of innovative product and process technologies, production of cleanroom molding products and assemblies, ready to use sterile products, invasive medical devices and combination products with specialized drug and device platforms.

Robert earned a BA from the University of Toledo and holds ASQ Certifications in Quality Auditing, Engineering and Management.

“Having worked closely with the founders of Sharps Technology over the past several years, I learned about the purpose and capabilities for their specialty syringe technology. The company’s ability to provide a product that could create additional vaccine doses at no additional cost and deliver a safe injection that would protect both patients and healthcare providers, resonated with my personal reasons for working within the healthcare industry for the past 25+ years. Sharps Technology is an innovative medical device company that is well positioned within the specialty syringe segment. The company’s FDA approved technologies support the immediate needs of the healthcare market including COVID-19 vaccinations. Through the passion of the company’s employees and the company’s commitment to quality and innovation, I am very optimistic as I look ahead to achieve the growth potential for Sharps Technology,” adds Robert Hayes.

Soren Christiansen, Chairman of the Board, said, “Sharps Technology has been seeking an engineering, manufacturing and sales-oriented executive to lead the company as we increase manufacturing and commence commercialization of our Sharps Provensa™ smart safety syringes to meet COVID-19, and market demands. We look forward to Robert leading our company.”

About Sharps Technology

Sharps Technology offers a solution to a global healthcare crisis. Sharps Provensa Ultra-Low Waste™ smart safety syringes are the first of their kind designed to eliminate over two million potentially infectious, accidental needlestick injuries, as well as billions of dollars in medicine wasted with today’s inefficient syringes. Sharps Provensa™ syringes address the important needs of the global healthcare market:

  • Provides automatic protection from accidental needlestick injury for clinicians and all who come in contact with contaminated needles.
  • Prevents improper reuse of both needle and syringe by automatically locking the plunger and shielded needle following injection.
  • Sharps Provensa Ultra Low-Waste™ dramatically reduces the number of costly medications discarded with inefficient injections.
  • Facilitates extra doses from vials and pre-filled syringes.

Our proprietary Sharps Provensa™ safety syringes are the solution to urgent problems. We believe in caring through innovation. We believe that injections should not cause infections.

Company Contact:

Alan Blackman, Co-Chairman & Chief Investment Officer
Sharps Technology

Investor Relations Contact:

Dave Gentry, CEO
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498

SOURCE: Sharps Technology

View source version on

error: Content is protected !!